A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication

Published:2024-05 Issue: Volume:225 Page:105859
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Moon Christopher^ORCID,Porges Eleanor,Roberts Adam,Bacon Joanna

Publisher

Elsevier BV

Reference36 articles.

1. Effects of previous infection and vaccination on symptomatic omicron infections;Altarawneh;N. Engl. J. Med.,2022

2. Clinical pharmacokinetics of ombitasvir;Badri;Clin. Pharmacokinet.,2017

3. Synergistic and antagonistic drug combinations against SARS-CoV-2;Bobrowski;Mol. Ther.,2021

4. Therapeutic strategies to combat antibiotic resistance;Brooks;Adv. Drug Deliv. Rev.,2014

5. Candidate binding sites for allosteric inhibition of the SARS-CoV - 2 main protease from the analysis of large-scale molecular dynamics simulations;Carli;Phys. Chem. Lett.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of SARS-CoV-2 nsp14 Proofreading on Nucleoside Antiviral Activity: Insights from Genetic and Pharmacological Investigations;2024-07-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP